--- title: "Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/288599314.md" description: "Aurinia Pharmaceuticals CEO Kevin Tang purchased 814,606 shares worth $12.46M on June 3, signaling confidence in the stock. Following the insider buy, Aurinia's shares rose 2.47% to $15.98. The biopharma company reported strong financials, including 24.4% revenue growth, a 91.63% gross margin, and an undervalued P/E ratio of 7.12 compared to industry peers." datetime: "2026-06-03T15:01:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288599314.md) - [en](https://longbridge.com/en/news/288599314.md) - [zh-HK](https://longbridge.com/zh-HK/news/288599314.md) --- # Chief Executive Officer Of Aurinia Pharmaceuticals Makes $12.46M Buy On June 3, **KEVIN TANG**, Chief Executive Officer at **Aurinia Pharmaceuticals** (NASDAQ:AUPH) executed a significant insider buy, as disclosed in the latest SEC filing. **What Happened:** TANG made a significant move by purchasing 814,606 shares of Aurinia Pharmaceuticals as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth stands at $12,455,227. The latest update on Wednesday morning shows **Aurinia Pharmaceuticals** shares up by 2.47%, trading at $15.98. ### Discovering Aurinia Pharmaceuticals: A Closer Look Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. ### Financial Insights: Aurinia Pharmaceuticals **Revenue Growth:** Over the 3 months period, Aurinia Pharmaceuticals showcased positive performance, achieving a revenue growth rate of **24.4%** as of 31 March, 2026. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector. **Insights into Profitability:** - Gross Margin: The company excels with a remarkable gross margin of 91.63%, indicating superior cost efficiency and profitability compared to its industry peers. - Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 0.26, Aurinia Pharmaceuticals showcases strong earnings per share. **Debt Management:** Aurinia Pharmaceuticals's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of **0.12**. **Financial Valuation Breakdown:** - Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 7.12 is lower than the industry average, indicating potential undervaluation for the stock. - Price to Sales (P/S) Ratio: The current P/S ratio of 7.08 is above industry norms, reflecting an elevated valuation for Aurinia Pharmaceuticals's stock and potential overvaluation based on sales performance. - EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Aurinia Pharmaceuticals's EV/EBITDA ratio at 10.6 suggests potential undervaluation, falling below industry averages. **Market Capitalization:** Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition. ### The Importance of Insider Transactions Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis. From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction. A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock. While insider sells may not necessarily reflect a bearish view and can be motivated by various factors. ### A Closer Look at Important Transaction Codes For investors, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A **P** in Box 3 denotes a purchase, while **S** signifies a sale. Transaction code **C** signals the conversion of an option, and transaction code **A** denotes a grant, award, or other acquisition of securities from the company. Check Out The Full List Of Aurinia Pharmaceuticals's Insider Trades. _This article was generated by Benzinga's automated content engine and reviewed by an editor._ ### Related Stocks - [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md) ## Related News & Research - [Diamond Hill Capital Management LLC Investment Advisor Purchases New Position in Aurinia Pharmaceuticals Inc $AUPH](https://longbridge.com/en/news/296195979.md) - [Andar Capital Management HK Ltd Takes $4.32 Million Position in FormFactor, Inc. $FORM](https://longbridge.com/en/news/296068767.md) - [Apollo Global Management files Form 3 initial beneficial ownership statement for LDB 2025 LLC](https://longbridge.com/en/news/295974245.md) - [Insider Decision: Anthony Ibarguen Offloads $619K Worth Of Insight Enterprises Stock](https://longbridge.com/en/news/296247689.md) - [Rocket Companies director Sarah Watterson files Form 3 initial beneficial ownership statement](https://longbridge.com/en/news/296141298.md)